SOUTH SAN FRANCISCO, Calif., Nov 8, 2016 – Fluidigm Corporation (NASDAQ:FLDM) and GenomOncology today announced a distribution agreement to co-market the GO Clinical Workbench™ for molecular interpretation of somatic variants identified using Fluidigm systems. An elegant solution for clinical research laboratories seeking accuracy, flexibility, and scalability, this combined offering will enable laboratories to achieve greater workflow efficiencies and productivity from NGS library preparation, variant annotation and reporting.
Fluidigm currently provides highly-scalable workflows for NGS library preparation that offer significant cost savings and workflow improvements over the largely manual, low-throughput library preparation workflows available today. Utilizing the Juno™ Targeted DNA Sequencing Library Preparation System, a wide range of panels can easily be produced, from targeted multiplexed panels covering a few user‑defined genes to more comprehensive panels of 4,800 or more amplicons from hundreds of genes. With the additional flexibility to add new markers over time, laboratories can also be well-positioned to meet the demands of NGS library preparation today and well into the future. Fluidigm plans to further expand this offering by developing NGS somatic mutation panels together with optimized automated library preparation protocols for use with the Juno system.
GenomOncology and Fluidigm plan to co-market the Juno targeted NGS library preparation workflow for use with the GO Clinical Workbench, a proven knowledge-enabled software solution that provides decision support to enable precision oncology research programs.
The GO Clinical Workbench is built upon a foundation of expert knowledge curated by My Cancer Genome, which provides information related to cancer genes and variants, targeted therapies, prognostic implications, clinical trials, and cell-signaling pathways. This knowledge base, augmented with information from FDA, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO), and other annotation sources, is readily available via the GO Clinical Workbench.
In support of this partnership, Fluidigm and GenomOncology plan to co-present in the Fluidigm Corporate Workshop at the American Molecular Pathology (AMP) annual meeting on November 9 in Charlotte, North Carolina.
“We are pleased to partner with Fluidigm to provide an integrated offering that will enable more laboratories to meet the increasing demands of molecular tumor screening and reporting,” said Manuel Glynias, CEO of GenomOncology. “Fluidigm is well-recognized for delivering trusted performance while providing significant improvements in laboratory productivity, a goal that we both share.”
“GenomOncology is leading the way in developing easy-to-use tools to streamline somatic mutation profiling and variant reporting” said Chris Linthwaite, President and CEO of Fluidigm. “We look forward to providing these industry-leading tools to our customers and further expanding this combined offering with NGS oncology panels for translational and clinical research. Together with our customers, we look forward to seeing the benefits these solutions will bring to the cancer community.”
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements relating to features and benefits of a combined product offering and benefits from, and activities under, a co-marketing agreement. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including, but not limited to, risks relating to the future financial performance of Fluidigm product lines and challenges inherent in developing, manufacturing, launching, marketing, and selling new products, including reliance on third parties for co-marketing and collaboration and competition. Information on these and additional risks, uncertainties, and other information affecting Fluidigm business and operating results are contained in Fluidigm’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law.
Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for growth markets such as single-cell biology and production genomics. We sell to leading academic institutions, clinical laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multiparameter mass cytometry technology and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
We use our website (www.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (https://www.facebook.com/Fluidigm), and LinkedIn page (https://www.linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.
Fluidigm, the Fluidigm logo, and Juno are trademarks or registered trademarks of Fluidigm Corporation.
GenomOncology is a health care technology company enabling precision medicine by transforming genomic data into actionable information. Learn more at www.genomoncology.com.